ImmunityBio (IBRX) Equity Average: 2015-2025
Historic Equity Average for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to -$547.5 million.
- ImmunityBio's Equity Average rose 24.03% to -$547.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$547.5 million, marking a year-over-year increase of 24.03%. This contributed to the annual value of -$538.0 million for FY2024, which is 3.79% down from last year.
- As of Q3 2025, ImmunityBio's Equity Average stood at -$547.5 million, which was up 5.77% from -$581.1 million recorded in Q2 2025.
- ImmunityBio's 5-year Equity Average high stood at -$151.9 million for Q1 2021, and its period low was -$720.8 million during Q3 2024.
- Over the past 3 years, ImmunityBio's median Equity Average value was -$581.1 million (recorded in 2025), while the average stood at -$585.9 million.
- Per our database at Business Quant, ImmunityBio's Equity Average plummeted by 6,850.95% in 2021 and then climbed by 24.03% in 2025.
- ImmunityBio's Equity Average (Quarterly) stood at -$216.9 million in 2021, then tumbled by 102.58% to -$439.5 million in 2022, then fell by 13.51% to -$498.8 million in 2023, then decreased by 23.62% to -$616.6 million in 2024, then grew by 24.03% to -$547.5 million in 2025.
- Its Equity Average was -$547.5 million in Q3 2025, compared to -$581.1 million in Q2 2025 and -$540.3 million in Q1 2025.